SCM Lifescience Co., Ltd. (KOSDAQ:298060)

Market Cap	34.53B
Revenue (ttm)	1.17B
Net Income (ttm)	-10.70B
Shares Out	32.76M
EPS (ttm)	-480.49
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	182,386
Average Volume	1,844,274
Open	1,045.00
Previous Close	1,053.00
Day's Range	1,009.00 - 1,074.00
52-Week Range	792.00 - 3,155.00
Beta	1.15
RSI	49.07
Earnings Date	n/a

About Revance Therapeutics

SCM Lifescience Co., Ltd. operates in the stem cell therapy, CMO, contract research and consulting, and cosmetic businesses. The company develops allogeneic stem cell therapeutics using its stem cell isolation technology and conducting clinical trials for immunological conditions and tissue regeneration; provides CMO services for manufacturing control and quality assurance tests; and offers adult stem cell research services. It also provides skin cell science services. The company was founded in 2014 and is headquartered in Incheon, South Korea...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2014
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 298060

Financial Performance

In 2024, SCM Lifescience's revenue was 824.80 million, an increase of 18.56% compared to the previous year's 695.70 million. Losses were -12.38 billion, -48.35% less than in 2023.